Clinical Trial Update: Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) [Phase 1]

View source ↗

Summary

This Phase 1 study assessed the feasibility and preliminary efficacy of neoadjuvant cabozantinib plus nivolumab followed by definitive resection in patients wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Locally Advanced Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED